196 related articles for article (PubMed ID: 8614853)
21. [Impact of the chemotherapy protocols for metastatic breast cancer on the treatment cost and the survival time of 371 patients treated in three hospitals of the Rhone-Alpes region].
Paviot BT; Bachelot T; Clavreul G; Jacquin JP; Mille D; Rodrigues JM
Bull Cancer; 2009 Oct; 96(10):929-40. PubMed ID: 19696006
[TBL] [Abstract][Full Text] [Related]
22. Pharmacoeconomic aspects of adjuvant anastrozole or tamoxifen in breast cancer: a Slovenian perspective.
Piskur P; Sonc M; Cufer T; Borstnar S; Mrhar A
Anticancer Drugs; 2006 Jul; 17(6):719-24. PubMed ID: 16917219
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of 21-gene assay in node-positive, early-stage breast cancer.
Vanderlaan BF; Broder MS; Chang EY; Oratz R; Bentley TG
Am J Manag Care; 2011; 17(7):455-64. PubMed ID: 21819166
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of endocrine therapy in the treatment of breast cancer.
Wait SH
Anticancer Drugs; 1998 Nov; 9(10):849-57. PubMed ID: 9890696
[TBL] [Abstract][Full Text] [Related]
25. Costs, effects and cost-effectiveness of breast cancer control in Ghana.
Zelle SG; Nyarko KM; Bosu WK; Aikins M; Niëns LM; Lauer JA; Sepulveda CR; Hontelez JA; Baltussen R
Trop Med Int Health; 2012 Aug; 17(8):1031-43. PubMed ID: 22809238
[TBL] [Abstract][Full Text] [Related]
26. Principles of therapy in advanced breast cancer.
Ingle JN
Hematol Oncol Clin North Am; 1989 Dec; 3(4):743-63. PubMed ID: 2481669
[TBL] [Abstract][Full Text] [Related]
27. Economic analysis of gene expression profile data to guide adjuvant treatment in women with early-stage breast cancer.
Cosler LE; Lyman GH
Cancer Invest; 2009 Dec; 27(10):953-9. PubMed ID: 19909009
[No Abstract] [Full Text] [Related]
28. [Cost effectiveness evaluation of breast cancer therapy. Comparative analysis 1975-1985 in a cancer prevention center].
Lapeyre-Mestre M; Daly-Schveitzer N; Boussin G; Delande G
Rev Epidemiol Sante Publique; 1993; 41(5):397-406. PubMed ID: 8284480
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen.
van Nuland M; Vreman RA; Ten Ham RMT; de Vries Schultink AHM; Rosing H; Schellens JHM; Beijnen JH; Hövels AM
Breast Cancer Res Treat; 2018 Nov; 172(1):143-150. PubMed ID: 30006796
[TBL] [Abstract][Full Text] [Related]
30. Tamoxifen: a review of pharmacoeconomic and quality-of-life considerations for its use as adjuvant therapy in women with breast cancer.
Bryson HM; Plosker GL
Pharmacoeconomics; 1993 Jul; 4(1):40-66. PubMed ID: 10146967
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen should be cost-effective in reducing breast cancer risk in high-risk women.
Smith TJ; Hillner BE
J Clin Oncol; 2000 Jan; 18(2):284-6. PubMed ID: 10637241
[TBL] [Abstract][Full Text] [Related]
32. Cost-Effectiveness Modeling of Surgery Plus Adjuvant Endocrine Therapy Versus Primary Endocrine Therapy Alone in UK Women Aged 70 and Over With Early Breast Cancer.
Holmes GR; Ward SE; Brennan A; Bradburn M; Morgan JL; Reed MWR; Richards P; Rafia R; Wyld L;
Value Health; 2021 Jun; 24(6):770-779. PubMed ID: 34119074
[TBL] [Abstract][Full Text] [Related]
33. Economic/societal burden of metastatic breast cancer: a US perspective.
Allen JM
Am J Manag Care; 2010 Sep; 16(9):697-704. PubMed ID: 20873957
[TBL] [Abstract][Full Text] [Related]
34. A review of systematic reviews of the cost-effectiveness of hormone therapy, chemotherapy, and targeted therapy for breast cancer.
Diaby V; Tawk R; Sanogo V; Xiao H; Montero AJ
Breast Cancer Res Treat; 2015 May; 151(1):27-40. PubMed ID: 25893588
[TBL] [Abstract][Full Text] [Related]
35. Cost-benefit of laparoscopic versus medical ovarian suppression in premenopausal breast cancer.
Hagemann AR; Zighelboim I; Odibo AO; Rader JS; Mutch DG; Powell MA
Breast J; 2011; 17(1):103-5. PubMed ID: 21155918
[No Abstract] [Full Text] [Related]
36. Impact of Nonconcordance With NCCN Guidelines on Resource Utilization, Cost, and Mortality in De Novo Metastatic Breast Cancer.
Rocque GB; Williams CP; Jackson BE; Ingram SA; Halilova KI; Pisu M; Kenzik KM; Azuero A; Forero A; Bhatia S
J Natl Compr Canc Netw; 2018 Sep; 16(9):1084-1091. PubMed ID: 30181420
[No Abstract] [Full Text] [Related]
37. Management of primary breast cancer: an update.
Thürlimann B; Müller A; Senn HJ
Onkologie; 2004 Apr; 27(2):175-9. PubMed ID: 15138352
[TBL] [Abstract][Full Text] [Related]
38. Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.
Benedict A; Brown RE
Expert Opin Pharmacother; 2005 Sep; 6(11):1789-801. PubMed ID: 16144501
[TBL] [Abstract][Full Text] [Related]
39. Chemotherapy culture differences persist, but molecular insights foster change.
Benowitz S
J Natl Cancer Inst; 2012 Apr; 104(8):576-8. PubMed ID: 22472544
[No Abstract] [Full Text] [Related]
40. [Palliative therapeutic control of tumor progression in patients with metastatic breast cancer].
Possinger K; Wilmanns W
Internist (Berl); 1993 Apr; 34(4):340-50. PubMed ID: 7683634
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
